BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $399,036 | +0.7% | 56,361 | +0.2% | 0.00% | 0.0% |
| Q2 2023 | $396,148 | -15.6% | 56,271 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $469,300 | -27.4% | 56,271 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $645,991 | -16.2% | 56,271 | -8.0% | 0.00% | 0.0% |
| Q3 2022 | $771,000 | +19.2% | 61,181 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $647,000 | -35.0% | 61,181 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $995,000 | -3.2% | 61,181 | -17.6% | 0.00% | 0.0% |
| Q4 2021 | $1,028,000 | -3.7% | 74,221 | -0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,067,000 | -9.0% | 74,222 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,173,000 | +70.2% | 74,222 | +9.6% | 0.00% | +100.0% |
| Q1 2021 | $689,000 | +36.4% | 67,748 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $505,000 | +123.5% | 67,748 | +3.1% | 0.00% | 0.0% |
| Q3 2020 | $226,000 | -27.8% | 65,718 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $313,000 | +189.8% | 65,718 | +21.6% | 0.00% | – |
| Q1 2020 | $108,000 | -42.6% | 54,064 | -0.7% | 0.00% | – |
| Q4 2019 | $188,000 | +20.5% | 54,434 | 0.0% | 0.00% | – |
| Q3 2019 | $156,000 | -24.3% | 54,434 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $206,000 | -53.5% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $443,000 | +0.9% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $439,000 | +5.8% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $415,000 | +33.0% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $312,000 | +20.0% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $260,000 | -2.6% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $267,000 | -6.3% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $285,000 | -5.9% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $303,000 | -33.7% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $457,000 | +32.5% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $345,000 | +43.8% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $240,000 | +54.8% | 54,434 | 0.0% | 0.00% | – |
| Q2 2016 | $155,000 | +0.6% | 54,434 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $154,000 | -72.6% | 54,434 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $562,000 | -9.5% | 54,434 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $621,000 | -23.6% | 54,434 | 0.0% | 0.00% | -33.3% |
| Q2 2015 | $813,000 | +68.3% | 54,434 | +1.8% | 0.00% | +50.0% |
| Q1 2015 | $483,000 | -25.2% | 53,481 | +0.7% | 0.00% | 0.0% |
| Q4 2014 | $646,000 | +24.2% | 53,126 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $520,000 | -23.2% | 53,126 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $677,000 | +991.9% | 53,126 | +32.4% | 0.00% | – |
| Q2 2013 | $62,000 | – | 40,133 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |